newsfilter
← Latest News
GlobeNewswire·

Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting

BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today